Related Experiment Video
Updated: Sep 27, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.4K
Stereotactic radiotherapy for adrenal oligometastases
Simona Borghesi1, Franco Casamassima2, Cynthia Aristei3
1Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Italy.
Summary
Stereotactic radiotherapy (SRT) effectively treats adrenal gland metastases from various cancers, achieving high local control rates (up to 90%) with minimal toxicity. Doses of 25-48 Gy in 3-10 fractions are common, with excellent outcomes when biologically effective doses exceed 100 Gy.
Area of Science:
- Oncology
- Radiotherapy
- Medical Imaging
Background:
- Adrenal gland metastases are common in melanoma, lung, breast, renal, and gastrointestinal cancers.
- Accurate diagnosis relies on imaging techniques like CT, MRI, and 18F-FDG PET-CT.
Purpose of the Study:
- To evaluate the efficacy and toxicity of stereotactic radiotherapy (SRT) for adrenal gland metastases.
- To determine optimal dosing and fractionation for SRT in this context.
Main Methods:
- Review of imaging modalities for adrenal metastasis diagnosis.
- Analysis of stereotactic radiotherapy (SRT) doses, fractionation, and outcomes.
- Assessment of local control rates and toxicity profiles.
Main Results:
- Local control rates at 1 and 2 years range from 44-100% and 27-100%, respectively.
- High local control (up to 90%) is achieved with biologically effective doses (BED10Gy) ≥ 100 Gy.
- SRT-related toxicity is generally mild, with rare instances of adrenal insufficiency.
Conclusions:
- Stereotactic radiotherapy (SRT) is an effective treatment for adrenal gland metastases.
- Optimal dosing and fractionation strategies can maximize local control while minimizing toxicity.
